(Q38012165)

27 August 2017

title

The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia (English)

1 reference

27 August 2017

0 references

1 reference

Lukáš Smolej

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

23 May 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

published in

1 reference

27 August 2017

volume

21

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

1009-1017

1 reference

Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Allotransplantation for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Treatment of fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

The human glucocorticoid receptor: one gene, multiple proteins and diverse responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Glucocorticoid receptor expression in receptorless mutants isolated from the human leukemic cell line CEM-C7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Effects of glucocorticoids on apoptosis and clearance of apoptotic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Molecular mechanisms of corticosteroid resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Recent insights into the mechanism of glucocorticosteroid-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Apoptosis induction by the glucocorticoid hormone dexamethasone and the calcium-ATPase inhibitor thapsigargin involves Bc1-2 regulated caspase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Importance of genetics in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Understanding and managing ultra high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Prevention and treatment of systemic glucocorticoid side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Infections associated with steroid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Adrenocorticotropic hormone- and cortisone-induced regression of lymphoid tumors in man; a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

WEEKLY HIGH-DOSAGE GLUCOCORTICOSTEROID TREATMENT OF LYMPHOCYTIC LEUKEMIAS AND LYMPHOMAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

The treatment of chronic lymphocytic leukemia with COP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Autoimmune complications of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Autoimmune complications in chronic lymphocytic leukaemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.690393

10.1517/13543784.2012.690393

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference